ReCode Therapeutics secured up to $15 million in a corporate round led by the Cystic Fibrosis Foundation to develop a gene editing therapy for cystic fibrosis.

Nov 18, 2024•about 1 year ago

Amount Raised

$15 Million

Menlo ParkBiotechnologyHealth Care

Investors

Cystic Fibrosis Foundation

Description

The Cystic Fibrosis Foundation has agreed to invest up to $15 million in ReCode Therapeutics to support their collaboration with Intellia Therapeutics. The funding will aid in the development of a gene editing therapy intended for lung cells of individuals suffering from cystic fibrosis.

Company Information

Company

ReCode Therapeutics

Location

Menlo Park, California, United States

About

ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends